Integrating Halotherapy Into Preseason Training Improves Respiratory and Aerobic Performance in Elite Female Soccer Players
1 other identifier
interventional
28
1 country
1
Brief Summary
This randomized controlled trial aimed to investigate the effects of a 12-week halotherapy intervention on respiratory muscle strength, pulmonary function, aerobic capacity, and intermittent running performance in elite female soccer players. Participants were randomly assigned to either a halotherapy group or a control group. Both groups followed the same preseason soccer training program, while the halotherapy group additionally received regular halotherapy sessions. Pre- and post-intervention assessments included spirometric measurements, respiratory muscle strength, estimated VO₂max, and Yo-Yo Intermittent Recovery Test Level 1 performance.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 5, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
July 20, 2022
CompletedFirst Submitted
Initial submission to the registry
February 6, 2026
CompletedFirst Posted
Study publicly available on registry
February 12, 2026
CompletedFebruary 12, 2026
February 1, 2026
3 months
February 6, 2026
February 6, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Maximal Expiratory Pressure (MEP)
Expiratory muscle strength measured using a portable respiratory pressure meter.
12 week
Maximal Inspiratory Pressure (MIP)
Inspiratory muscle strength measured using a portable respiratory pressure meter.
12 week
Aerobic Capacity (VO₂max estimate)
VO₂max estimated using the Yo-Yo Intermittent Recovery Test Level 1.
12 week
Secondary Outcomes (4)
Forced Vital Capacity (FVC)
12 week
Forced Expiratory Volume in 1 Second (FEV₁)
12 weeks
Peak Expiratory Flow (PEF)
12 week
Yo-Yo Intermittent Recovery Test Level 1 Distance
12 week
Study Arms (2)
Halotherapy Group
EXPERIMENTALParticipants followed the standard preseason soccer training program and additionally received halotherapy. Halotherapy sessions were conducted in a controlled halochamber using a dry salt aerosol generator. Sessions lasted 45 minutes and were performed three times per week for 12 weeks. Aerosol concentration was maintained at approximately 20 mg/m³ with particle size \<5 microns. Environmental conditions were controlled (temperature 20-24°C, humidity 40-60%).
CONTROL
NO INTERVENTIONParticipants followed the same standard preseason soccer training program without halotherapy.
Interventions
Participants followed the standard preseason soccer training program and additionally received halotherapy. Halotherapy sessions were conducted in a controlled halochamber using a dry salt aerosol generator. Sessions lasted 45 minutes and were performed three times per week for 12 weeks. Aerosol concentration was maintained at approximately 20 mg/m³ with particle size \<5 microns. Environmental conditions were controlled (temperature 20-24°C, humidity 40-60%).
Participants followed the same standard preseason soccer training program without halotherapy.
Eligibility Criteria
You may qualify if:
- Female soccer players aged 18-30 years
- Competing in the Turkish Women's First League
- Minimum of 5 years of competitive soccer experience
- Regular training ≥10 hours per week
- Free from injury at study entry
- Non-smokers
- Not using chronic medication
- Provided written informed consent
You may not qualify if:
- Presence of respiratory, cardiovascular, or metabolic disease
- Current musculoskeletal injury
- Smoking
- Pregnancy
- Use of medications affecting respiratory or cardiovascular function
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Gumushane Univetsity
Gümüşhane, Trabzon, Ordu, Giresun, Rize, Artvin, Gümüşhane, 29600, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
February 6, 2026
First Posted
February 12, 2026
Study Start
April 5, 2022
Primary Completion
July 15, 2022
Study Completion
July 20, 2022
Last Updated
February 12, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared because the study involves a small sample of elite athletes from a single professional team, which may increase the risk of indirect participant identification. Additionally, the informed consent obtained from participants did not include explicit permission for public sharing of individual-level data. Data are therefore available only in aggregated form to protect participant confidentiality.